Drug Profile
RST 001
Alternative Names: RST-001Latest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator Wayne State University
- Developer RetroSense Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Retinitis pigmentosa
Most Recent Events
- 27 Sep 2021 Phase-I/II development of RST 001 is ongoing in USA (NCT02556736)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 03 Dec 2018 Phase-I/II development is ongoing in USA (NCT02556736)